SCHEMBL885547

SCHEMBL885547

Fc1ccc(CC(c2cccnc2)c2cccnc2)c(-c2ccc3c(c2)OCO3)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNA5 P22460 10/20 0.62
KCNH2 Q12809 7/20 0.62
CLK1 P49759 2/20 0.44
DYRK1A Q13627 2/20 0.44
CLK4 Q9HAZ1 2/20 0.44
KDM4E B2RXH2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
HPGD P15428 2/20 0.44
HSD17B10 Q99714 2/20 0.44
TDP1 Q9NUW8 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
CYP2D6 P10635 1/20 0.44
CYP2C9 P11712 1/20 0.44
TSHR P16473 1/20 0.44
CYP2C19 P33261 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2063823 0.95 KCNA5 (0.61) KCNA5KCNH2CLK1DYRK1ACLK4
SCHEMBL2063205 0.86 KCNA5 (0.66) KCNA5KCNH2CLK1DYRK1ACLK4
SCHEMBL2063360 0.85 KCNA5 (0.71) KCNA5KCNH2CYP11B1CYP11B2
SCHEMBL2062791 0.82 KCNA5 (0.74) KCNA5KCNH2TSHRCYP11B1CYP11B2
SCHEMBL2062737 0.81 KCNA5 (0.69) KCNA5KCNH2CYP11B1CYP11B2
SCHEMBL2062402 0.81 KCNA5 (0.64) KCNA5KCNH2CLK1DYRK1ACLK4
SCHEMBL2062772 0.81 KCNA5 (0.65) KCNA5KCNH2
SCHEMBL2063320 0.81 KCNA5 (0.65) KCNA5KCNH2NPC1RAB9A
SCHEMBL886549 0.79 KCNA5 (0.63) KCNA5KCNH2CLK1DYRK1ACLK4
SCHEMBL2063132 0.79 KCNA5 (0.80) KCNA5KCNH2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US claimed
EP-1940406-A2 POTASSIUM CHANNEL INHIBITORS Merck and Co., Inc. (US) 2008-07-09 EP claimed
WO-2007050348-A2 POTASSIUM CHANNEL INHIBITORS MERCK & CO., INC. (US) 2007-05-03 WO claimed
US-8148535-B2 Potassium channel inhibitors MERCK SHARP & DOHME CORP. (US) 2012-04-03 US disclosed
US-20090233897-A1 Potassium Channel Inhibitors MERCK SHARP & DOHME CORP. 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233897-A1 Potassium Channel Inhibitors KCNJ2, KCNQ2, KCNH2 KCNA5 11/4885KCNH2 3/4885CLK1 705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.